Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Vivek Lal
Robert JM Brummer MD PhD
Rikke Nielson
Fabio Grassi
Eric Van der Helm
Dev Verma
Dev graduated from Columbia University in 2007 with an undergraduate degree in biochemistry (summa cum laude), Harvard Medical School in 2011, and completed his plastic and reconstructive surgery residency training at Georgetown University Hospital in 2018. For several years he worked as a private practice plastic surgeon, with a focus on complex wound care. In 2020 he transitioned his career to pharmaceutical drug regulation and began working as a medical officer clinical reviewer in the Division of Dermatology and Dentistry in the Center for Drug Evaluation and Research (CDER) at FDA. He is an active participant in the Wound Care Collaborative Community (WCCC) and is optimistic that continued FDA engagement with external stakeholders working in the wound care space will ultimately lead to safe, effective, and innovative products for patients.